AU2021260923B2 - New dry powder composition for peroral administration - Google Patents

New dry powder composition for peroral administration

Info

Publication number
AU2021260923B2
AU2021260923B2 AU2021260923A AU2021260923A AU2021260923B2 AU 2021260923 B2 AU2021260923 B2 AU 2021260923B2 AU 2021260923 A AU2021260923 A AU 2021260923A AU 2021260923 A AU2021260923 A AU 2021260923A AU 2021260923 B2 AU2021260923 B2 AU 2021260923B2
Authority
AU
Australia
Prior art keywords
mannitol
mixing
pct
rsd
blend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021260923A
Other languages
English (en)
Other versions
AU2021260923A1 (en
Inventor
Ola Camber
Arnout EVERAERT
Stefan GRUDÉN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of AU2021260923A1 publication Critical patent/AU2021260923A1/en
Application granted granted Critical
Publication of AU2021260923B2 publication Critical patent/AU2021260923B2/en
Priority to AU2026203700A priority Critical patent/AU2026203700A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021260923A 2020-04-24 2021-04-23 New dry powder composition for peroral administration Active AU2021260923B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026203700A AU2026203700A1 (en) 2020-04-24 2026-05-14 New dry powder composition for peroral administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006079.4A GB202006079D0 (en) 2020-04-24 2020-04-24 New composition
GB2006079.4 2020-04-24
PCT/GB2021/050994 WO2021214488A1 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203700A Division AU2026203700A1 (en) 2020-04-24 2026-05-14 New dry powder composition for peroral administration

Publications (2)

Publication Number Publication Date
AU2021260923A1 AU2021260923A1 (en) 2022-12-08
AU2021260923B2 true AU2021260923B2 (en) 2026-03-12

Family

ID=71080269

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021260923A Active AU2021260923B2 (en) 2020-04-24 2021-04-23 New dry powder composition for peroral administration
AU2026203700A Pending AU2026203700A1 (en) 2020-04-24 2026-05-14 New dry powder composition for peroral administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026203700A Pending AU2026203700A1 (en) 2020-04-24 2026-05-14 New dry powder composition for peroral administration

Country Status (19)

Country Link
US (2) US11844868B2 (cg-RX-API-DMAC7.html)
EP (2) EP4138790B1 (cg-RX-API-DMAC7.html)
JP (3) JP7387903B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230005220A (cg-RX-API-DMAC7.html)
CN (1) CN115697309A (cg-RX-API-DMAC7.html)
AU (2) AU2021260923B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021511A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180646A1 (cg-RX-API-DMAC7.html)
DK (1) DK4138790T3 (cg-RX-API-DMAC7.html)
ES (1) ES2976885T3 (cg-RX-API-DMAC7.html)
GB (1) GB202006079D0 (cg-RX-API-DMAC7.html)
IL (1) IL297373B2 (cg-RX-API-DMAC7.html)
LT (1) LT4138790T (cg-RX-API-DMAC7.html)
MX (1) MX2022013070A (cg-RX-API-DMAC7.html)
PL (1) PL4138790T3 (cg-RX-API-DMAC7.html)
PT (1) PT4138790T (cg-RX-API-DMAC7.html)
SI (1) SI4138790T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214488A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211460B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
KR20240148359A (ko) 2022-02-10 2024-10-11 바이코어 파마 아베 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139475A1 (en) * 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2019183513A1 (en) * 2018-03-22 2019-09-26 University Of Iowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
WO2005123072A1 (en) 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139475A1 (en) * 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2019183513A1 (en) * 2018-03-22 2019-09-26 University Of Iowa Research Foundation Compositions and methods for the treatment and prevention of muscular dystrophy

Also Published As

Publication number Publication date
EP4138790B1 (en) 2024-01-31
ES2976885T3 (es) 2024-08-12
JP2024020417A (ja) 2024-02-14
US20220202726A1 (en) 2022-06-30
BR112022021511A2 (pt) 2023-01-24
JP2023503178A (ja) 2023-01-26
ZA202211460B (en) 2025-02-26
EP4138790A1 (en) 2023-03-01
KR20230005220A (ko) 2023-01-09
WO2021214488A1 (en) 2021-10-28
US11844868B2 (en) 2023-12-19
US20240269081A1 (en) 2024-08-15
EP4389212A2 (en) 2024-06-26
US12605341B2 (en) 2026-04-21
JP2026099828A (ja) 2026-06-18
MX2022013070A (es) 2022-11-30
AU2021260923A1 (en) 2022-12-08
PT4138790T (pt) 2024-04-01
CN115697309A (zh) 2023-02-03
PL4138790T3 (pl) 2024-06-10
SI4138790T1 (sl) 2024-05-31
LT4138790T (lt) 2024-04-10
IL297373A (en) 2022-12-01
GB202006079D0 (en) 2020-06-10
IL297373B2 (en) 2026-05-01
EP4389212A3 (en) 2024-10-09
CA3180646A1 (en) 2021-10-28
DK4138790T3 (en) 2024-03-11
IL297373B1 (en) 2026-01-01
AU2026203700A1 (en) 2026-05-28
JP7387903B2 (ja) 2023-11-28

Similar Documents

Publication Publication Date Title
US12605341B2 (en) Dry powder composition for peroral administration
AU2021258542B2 (en) New delayed release composition for peroral administration
US20230149362A1 (en) New capsule composition for peroral administration
US12128029B2 (en) Treatment of idiopathic pulmonary fibrosis
HK40110823A (en) New dry powder composition for peroral administration
HK40088607A (en) New dry powder composition for peroral administration
HK40088607B (en) New dry powder composition for peroral administration
HK40090175A (en) New delayed release composition for peroral administration
HK40088609B (en) New delayed release composition for peroral administration
HK40088609A (en) New delayed release composition for peroral administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)